TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37659673
Drug: Guselkumab 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guselkumab 400 mg (nonresponders at week 12)
Study: 37660042
Drug: Control (Medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Medication and Traditional Physiotherapy)
Study: 37660052
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg dexamethasone
Study: 37660535
Drug: PD-1-based immunotherapy
Normalized name: Dianeal PD-2/1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1-based immunotherapy with tumor PD-L1 determined in lymph node metastases
Study: 37660535
Drug: PD-1-based immunotherapy
Normalized name: Dianeal PD-2/1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1-based immunotherapy with tumor PD-L1 determined in primary tumors
Study: 37660535
Drug: PD-1-based immunotherapy
Normalized name: Dianeal PD-2/1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1-based immunotherapy with tumor PD-L1 determined in skin/subcutaneous metastases
Study: 37660704
Drug: Placebo/Weekly dupilumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo/Weekly dupilumab
Study: 37660711
Drug: V160 three-dose
Normalized name: THREE-LOBE SAGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: V160 three-dose regimen (V160 at day 1, month 2, and month 6)
Study: 37660711
Drug: V160 two-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: V160 two-dose regimen (V160 on day 1, placebo at month 2, and V160 at month 6)
Study: 37660711
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline solution at day 1, month 2, and month 6)
Study: 37660711
Drug: V160 three-dose
Normalized name: THREE-LOBE SAGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: V160 three-dose regimen
Study: 37660711
Drug: V160 two-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: V160 two-dose regimen
Study: 37660952
Drug: Automated Self-Administered
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Automated Self-Administered 24-h recalls (ASA24s)
Study: 37661107
Drug: Intraduodenal infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraduodenal infusion of glucose (22.5 g, 1 kcal/min) and oleic acid (10 g, 1 kcal/min) for 90 min
Study: 37661107
Drug: Intraduodenal infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraduodenal infusion with benzocaine
Study: 37661107
Drug: Intraduodenal nutrient
Normalized name: Votrient
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intraduodenal nutrient infusion
Study: 37662520
Drug: Parsaclisib 20
Normalized name: Parsaclisib
DrugBank: Parsaclisib (DB14867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parsaclisib 20 mg once daily for 8 weeks then 2.5 mg QD (daily dosing group [DG])
Study: 37662520
Drug: Parsaclisib 20
Normalized name: Parsaclisib
DrugBank: Parsaclisib (DB14867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parsaclisib 20 mg once daily for 8 weeks then 20 mg once weekly (weekly dosing group [WG])
Study: 37662595
Drug: sucrosomial Vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sucrosomial Vitamin D3 (200,000 IU weekly)
Study: 37662595
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 treatment (not specified)
Study: 37663359
Drug: Informative booklet
Normalized name: INFORMATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Informative booklet and weekly phone calls for 6 weeks
Study: 37663593
Drug: Electroacupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture treatment (EA) using sacral acupoints
Study: 37663593
Drug: Electroacupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture treatment (EA) using abdominal acupoints
Study: 37663593
Drug: Electroacupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture treatment (EA) using alternating acupoints
Study: 37663593
Drug: Electroacupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture treatment (EA)
Study: 37664025
Drug: Lenvatinib (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenvatinib (20 mg/day) plus Pembrolizumab (200 mg every 3 weeks)
Study: 37664025
Drug: Sunitinib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib (50 mg/day, 4 weeks on, 2 weeks off)
Study: 37664560
Drug: Standard pfCa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pfCa monitoring (aiming pfCa level of 0.25-0.35 mmol/L)
Study: 37664560
Drug: No pfCa
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pfCa monitoring (constant citrate infusion at 4 mmol/L)
Study: 37665178
Drug: Selinexor 40
Normalized name: selinexor 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selinexor 40 mg/m2 with mitoxantrone, etoposide, and cytarabine (MEC)
Study: 37665397
Drug: Dexmedetomidine (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.15 µg kg continuous intravenous infusion)
Study: 37665497
Drug: Preservative-free oxybuprocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preservative-free oxybuprocaine hydrochloride 0.4% unit-dose eye drops, five times daily postoperatively until complete epithelial healing
Study: 37665565
Drug: Governmental non-pharmaceutical
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Governmental non-pharmaceutical interventions (NPI's)
Study: 37665877
Drug: General American
Approvals — FDA: no, EMA: no, PMDA: no
Description: General American College of Sports Medicine exercise prescription
Study: 37666264
Drug: Regorafenib combined
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib combined with nivolumab and FOLFOX chemotherapy
Study: 37666539
Drug: Olvimulogene nanivacirepvec
Normalized name: Olvimulogene nanivacirepvec
DrugBank: Olvimulogene nanivacirepvec (DB16268)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olvimulogene nanivacirepvec (Olvi-Vec) followed by platinum-doublet chemotherapy and bevacizumab
Study: 37666539
Drug: Platinum-doublet chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-doublet chemotherapy and bevacizumab
Study: 37667204
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose primaquine
Study: 37667213
Drug: L-PRF +
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-PRF + Collagen Membrane (CM)
Study: 37667507
Drug: HLA fully-mismatched
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLA fully-mismatched sibling-derived CD7 CAR-T therapy
Study: 37667847
Drug: 9-valent human
Normalized name: L1 protein, human papillomavirus type 31 vaccine
DrugBank: Human papillomavirus type 31 L1 capsid protein antigen (DB10310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9-valent human papillomavirus (9vHPV) vaccine
Study: 37668289
Drug: Canakinumab 150
Normalized name: canakinumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canakinumab 150 or 300 mg, either every 4 weeks or every 8 weeks, with up-titration permitted after on-treatment flares (maximum dose: 300 mg q4w)
Study: 37668289
Drug: Canakinumab 150
Normalized name: canakinumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canakinumab 150 or 300 mg
Study: 37668898
Drug: AK120 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: AK120 600 mg single ascending dose (SAD) in healthy subjects
Study: 37668898
Drug: AK120 multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: AK120 multiple ascending doses (300 mg Q2W, 300 mg QW, 150 mg QW, 75 mg QW) in subjects with AD
Study: 37669277
Drug: Pharmaceutical education
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pharmaceutical education about the correct use of antibiotic/s
Study: 37669281
Drug: Mindfulness-Based Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-Based Cognitive Therapy (MBCT) plus Supported Protocolized Discontinuation (SPD)
Study: 37669480
Drug: Selinexor (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selinexor (80 mg oral, once weekly)
Study: 37669842
Drug: Monthly medication
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly medication costs
Study: 37669842
Drug: Suboptimal medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suboptimal medication adherence
Study: 37670005
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of glucose and high-sensitivity cardiac troponin T (hs-cTnT)
Study: 37670005
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of glucose and high-sensitivity cardiac troponin I (hs-cTnI)
Study: 37670005
Drug: Dual-marker strategy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-marker strategy (glucose < 7 mmol/L and hs-cTnT < 5/hs-cTnI < 4 ng/L)
Study: 37670194
Drug: Early drain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early drain removal (EDR) on postoperative day 3 if serous and drain bilirubin level < 3 mg/dl (3×3 rule)
Study: 37670194
Drug: Routine drain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine drain removal (RDR) based on drain output being serous and < 100 ml
Study: 37670234
Drug: Individual characteristics
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual characteristics (e.g., CSF level of A[Formula: see text]).
Study: 37670579
Drug: Ciprofibrate 100
Normalized name: ciprofibrate 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofibrate 100 mg/d for 5 weeks
Study: 37670901
Drug: HP-β-CD 1500
Normalized name: HP-beta-CD
DrugBank: Hydroxypropyl betadex (DB15379)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP-β-CD 1500 mg/kg
Study: 37670901
Drug: HP-β-CD 2000
Normalized name: HP-beta-CD
DrugBank: Hydroxypropyl betadex (DB15379)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP-β-CD 2000 mg/kg
Study: 37670901
Drug: HP-β-CD 2500
Normalized name: HP-beta-CD
DrugBank: Hydroxypropyl betadex (DB15379)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP-β-CD 2500 mg/kg
Study: 37670901
Drug: HP-β-CD (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP-β-CD (all doses)
Study: 37671748
Drug: avelumab combined
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: avelumab combined with sacituzumab govitecan (anti-Trop-2/topoisomerase inhibitor conjugate)
Study: 37672016
Drug: Aripiprazole 2-Month
Normalized name: aripiprazole 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole 2-Month Ready-to-Use 960 mg
Study: 37672083
Drug: Antimicrobial photodynamic
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial photodynamic therapy (aPTD) combined with full-mouth disinfection
Study: 37672083
Drug: Antimicrobial photodynamic
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial photodynamic therapy (aPTD)
Study: 37672197
Drug: Vericiguat 2.5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vericiguat 2.5-10 mg
Study: 37672268
Drug: Valsartan (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (80 mg/d for children <35 kg, 160 mg/d for children ≥35 kg, 320 mg/d for adults)
Study: 37672548
Drug: Weekly primaquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly primaquine (PQ8W) at a dose of 0.75 mg/kg for 8 weeks plus dihydroartemisinin piperaquine or chloroquine
Study: 37672548
Drug: Weekly primaquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly primaquine (PQ8W)
Study: 37672566
Drug: Drug-releasing intratumoral
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Drug-releasing intratumoral microdevices (IMDs) used during tumor resection for 2 to 3 hours.
Study: 37672566
Drug: Drug-releasing intratumoral
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Drug-releasing intratumoral microdevices (IMDs) used during tumor resection.
Study: 37672598
Drug: Functional Assessment
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional Assessment of Cancer Therapy-General (FACT-G)
Study: 37672694
Drug: Atezolizumab (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab (1200 mg for patients ≥18 years; 15 mg/kg with a 1200 mg cap for patients <18 years) administered intravenously once every 21 days
Study: 37673112
Drug: Radical cytoreductive
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radical cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
Study: 37673112
Drug: Neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant therapy followed by surgery
Study: 37673453
Drug: 7-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day course of antibiotic treatment
Study: 37673453
Drug: 14-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day course of antibiotic treatment
Study: 37673858
Drug: Triplet maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triplet maintenance therapy (olaparib, pembrolizumab, bevacizumab)
Study: 37674214
Drug: Flexible outpatient
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible outpatient treatment model
Study: 37674358
Drug: Plasminogen, human-tvmh
Normalized name: plasminogen, human-tvmh
DrugBank: Plasminogen (DB16701)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasminogen, human-tvmh (6.6 mg/kg administered every 2-5 days for 48 weeks and every 1-7 days for up to 124 weeks)
Study: 37674711
Drug: 30-min daily
Normalized name: lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 30-min daily bright blue-green light (12,000 lux)
Study: 37674777
Drug: High-intensity interval
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity interval training (spinning) for 12 weeks, three times weekly
Study: 37675038
Drug: Controlled-release carbamazepine
Normalized name: carbamazepine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release carbamazepine (CBZ-CR) monotherapy
Study: 37675613
Drug: Rivaroxaban 20
Normalized name: rivaroxaban 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 20 mg daily for 180 days
Study: 37675613
Drug: Standard-of-care anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care anticoagulation (warfarin or low-molecular-weight heparin) for 180 days
Study: 37675828
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for recent HCV infection
Study: 37675901
Drug: Longer cumulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longer cumulative duration of antiretroviral therapies
Study: 37676105
Drug: Normal CC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal CC
Study: 37676110
Drug: Apatinib combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib combined with dose-dense paclitaxel and carboplatin (Apa+ddTCb)
Study: 37676110
Drug: Dose-dense paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose-dense paclitaxel plus carboplatin (ddTCb)
Study: 37676200
Drug: S-ICD (Subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-ICD (Subcutaneous Implantable Cardioverter-Defibrillator)
Study: 37676259
Drug: Tremelimumab in
Normalized name: tremelimumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tremelimumab in combination with durvalumab
Study: 37676612
Drug: Posaconazole 300
Normalized name: posaconazole 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posaconazole 300 mg IV/300 mg orally once daily (twice daily on day 1)
Study: 37676612
Drug: Voriconazole 4
Normalized name: voriconazole 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voriconazole 4 mg/kg IV twice daily/200 mg orally twice daily (6 mg/kg on day 1)
Study: 37676715
Drug: Home-based exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based exercise prehabilitation program (details on dosage and duration not available)
Study: 37677000
Drug: Melanocortin Pan-Agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melanocortin Pan-Agonist PL9643, dosage and duration not available
Study: 37677918
Drug: Cadonilimab 6
Normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadonilimab 6 mg/kg intravenously every 2 weeks in cohort A
Study: 37677918
Drug: Cadonilimab 6
Normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadonilimab 6 mg/kg intravenously every 2 weeks in cohort B
Study: 37677918
Drug: Cadonilimab 6
Normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadonilimab 6 mg/kg intravenously every 2 weeks in cohort C
Study: 37678222
Drug: Taurolidine/heparin catheter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taurolidine/heparin catheter lock solution (13.5 mg/ml taurolidine and 1000 units/ml heparin)
Study: 37678222
Drug: Heparin control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin control catheter lock solution (1000 units/ml)
Study: 37678222
Drug: Taurolidine/heparin catheter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taurolidine/heparin catheter lock solution
Study: 37678222
Drug: Taurolidine/heparin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taurolidine/heparin and Heparin
Study: 37678222
Drug: Taurolidine/heparin
Normalized name: TAUROLIDINE/HEPARIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taurolidine/heparin
Study: 37678257
Drug: Calpain inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calpain inhibitors
Study: 37678277
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with docetaxel, oxaliplatin, and capecitabine (DOX regimen)
Study: 37678277
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with oxaliplatin plus capecitabine (XELOX regimen)
Study: 37679276
Drug: gp145 C.6980
Approvals — FDA: no, EMA: no, PMDA: no
Description: gp145 C.6980 high dose (300 mcg), n = 25
Study: 37679276
Drug: gp145 C.6980
Approvals — FDA: no, EMA: no, PMDA: no
Description: gp145 C.6980 low dose (100 mcg), n = 15
Study: 37679276
Drug: gp145 C.6980
Approvals — FDA: no, EMA: no, PMDA: no
Description: gp145 C.6980 (both doses), n = 40
Study: 37679536
Drug: Mild CKD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild CKD (eGFR=60-89 mL/min/1.73 m²)
Study: 37679712
Drug: Remote monitoring
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remote monitoring intervention for managing heart failure, including tracking patients' weight and diuretic adherence.
Study: 37679723
Drug: CGRP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CGRP infusion (1.5 µg/min) over 20 min
Study: 37680795
Drug: Anti-cytokine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-cytokine treatment (tocilizumab in 53 patients, anakinra in 27 patients)
Study: 37680795
Drug: No anti-cytokine
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anti-cytokine treatment (77 patients)
Study: 37680795
Drug: Anti-cytokine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-cytokine treatment
Study: 37680942
Drug: CT017 CAR
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT017 CAR T cells at a dose of 250 × 10^6
Study: 37681568
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid plus docosahexaenoic acid (3.36 g/d) for 30 months
Study: 37682405
Drug: IND 75
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IND 75 µg
Study: 37682405
Drug: IND 150
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IND 150 µg
Study: 37682573
Drug: Adaptive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptive treatment with varenicline
Study: 37682573
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with varenicline
Study: 37682573
Drug: Adaptive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptive treatment with nicotine patches
Study: 37682573
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with nicotine patches
Study: 37682920
Drug: Ablative fractional
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ablative fractional CO2 laser treatment
Study: 37682953
Drug: Abemaciclib pre-operatively
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abemaciclib pre-operatively for 4.5 days at twice daily dosing
Study: 37682953
Drug: Abemaciclib therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abemaciclib therapy along with temozolomide
Study: 37683037
Drug: Neoadjuvant pembrolizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant pembrolizumab (anti-PD-1), 2 doses
Study: 37683048
Drug: Single plating
Normalized name: platinic chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single plating (standard locally available implant)
Study: 37683098
Drug: Long-Term Oxygen
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-Term Oxygen Therapy (LTOT)
Study: 37683122
Drug: Treatment strategies
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment strategies for pulmonary exacerbations in pediatric cystic fibrosis patients
Study: 37683234
Drug: Brexpiprazole Combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brexpiprazole Combination Therapy
Study: 37683276
Drug: FF-10850 +
Normalized name: FF-10501
DrugBank: FF-10501-01 (DB17554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF-10850 + anti-PD-1 antibody